SCHEMBL26606554

SCHEMBL26606554

Cc1ccc(Oc2ccc(C(=O)Nc3nc4ccccc4[nH]3)cc2)nn1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 15/20 0.67
▸ NPC1 O15118 14/20 0.67
▸ PKM P14618 7/20 0.67
▸ MEN1 O00255 4/20 0.67
▸ KMT2A Q03164 4/20 0.67
▸ KLF5 Q13887 3/20 0.64
▸ OPRK1 P41145 1/20 0.64
▸ MTOR P42345 1/20 0.60
▸ SMN1; SMN2 Q16637 7/20 0.59
▸ MAOB P27338 1/20 0.59
▸ ADORA2A P29274 1/20 0.59
▸ TP53 P04637 2/20 0.58
▸ KDM4E B2RXH2 2/20 0.58
▸ SCD O00767 1/20 0.58
▸ HSD17B10 Q99714 1/20 0.58
▸ MAPT P10636 2/20 0.56
▸ LMNA P02545 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26606450 0.89 RAB9A (0.69) RAB9ANPC1PKMMEN1KMT2A
SCHEMBL26606534 0.86 RAB9A (0.51) RAB9ANPC1PKMMEN1KMT2A
SCHEMBL26606459 0.85 IRAK4 (0.48) RAB9ANPC1PKMMEN1KMT2A
SCHEMBL11207978 0.81 RAB9A (1.00) RAB9ANPC1PKMMEN1KMT2A
SCHEMBL11703736 0.80 NPC1 (0.91) RAB9ANPC1PKMMEN1KMT2A
SCHEMBL11706816 0.79 NPC1 (1.00) RAB9ANPC1PKMMEN1KMT2A
SCHEMBL26606498 0.77 NPC1 (0.67) RAB9ANPC1MEN1KMT2AKLF5
SCHEMBL11702938 0.76 NPC1 (0.80) RAB9ANPC1PKMMEN1KMT2A
SCHEMBL3926899 0.76 NPC1 (1.00) RAB9ANPC1PKMMEN1KMT2A
SCHEMBL26606475 0.75 RAB9A (0.69) RAB9ANPC1PKMMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240116897-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2024-04-11 — — US disclosed
EP-4269394-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT Korea Research Institute of Chemical Technology (KR) 2023-11-01 — — EP disclosed
CN-116829542-A Benzothiazole and benzimidazole derivatives, pharmaceutically acceptable salts, preparation method thereof and pharmaceutical composition containing same as active ingredient 韩国化学研究院 2023-09-29 — — CN disclosed
WO-2022164135-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT 한국화학연구원 2022-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240116897-A1 BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT SIRT7, SIRT1, BRD7 RAB9A 2738/4885NPC1 1296/4885PKM 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback